Biblio

Export 305 results:
Author Title [ Type(Desc)] Year
Filters: First Letter Of Keyword is T  [Clear All Filters]
Journal Article
S. M. Shirgadwar, Kumar, R., Preeti, K., Khatri, D. Kumar, and Singh, S. Bala, “Neuroprotective Effect of Phloretin in Rotenone-Induced Mice Model of Parkinson's Disease: Modulating mTOR-NRF2-p62 Mediated Autophagy-Oxidative Stress Crosstalk.”, J Alzheimers Dis, vol. 94, no. s1, pp. S109-S124, 2023.
L. Guzmán-Martínez, Calfío, C., Farías, G. A., Vilches, C., Prieto, R., and Maccioni, R. B., “New Frontiers in the Prevention, Diagnosis, and Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 82, no. s1, pp. S51-S63, 2021.
M. Van Zeller, Dias, D., Sebastião, A. M., and Valente, C. A., “NLRP3 Inflammasome: A Starring Role in Amyloid-β- and Tau-Driven Pathological Events in Alzheimer's Disease.”, J Alzheimers Dis, vol. 83, no. 3, pp. 939-961, 2021.
S. Ramanan, Flanagan, E., Leyton, C. E., Villemagne, V. L., Rowe, C. C., Hodges, J. R., and Hornberger, M., “Non-Verbal Episodic Memory Deficits in Primary Progressive Aphasias are Highly Predictive of Underlying Amyloid Pathology.”, J Alzheimers Dis, vol. 51, no. 2, pp. 367-76, 2016.
D. Brici, Götz, J., and Nisbet, R. M., “A Novel Antibody Targeting Tau Phosphorylated at Serine 235 Detects Neurofibrillary Tangles.”, J Alzheimers Dis, vol. 61, no. 3, pp. 899-905, 2018.
H. B. Allen, “A Novel Approach to the Treatment and Prevention of Alzheimer's Disease Based on the Pathology and Microbiology.”, J Alzheimers Dis, vol. 84, no. 1, pp. 61-67, 2021.
H. B. Allen, “A Novel Approach to the Treatment and Prevention of Alzheimer's Disease Based on the Pathology and Microbiology.”, J Alzheimers Dis, vol. 84, no. 1, pp. 61-67, 2021.
H. Sandison, Callan, N. G. L., Rao, R. V., Phipps, J., and Bradley, R., “Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline.”, J Alzheimers Dis, vol. 94, no. 3, pp. 993-1004, 2023.
H. Sandison, Callan, N. G. L., Rao, R. V., Phipps, J., and Bradley, R., “Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline.”, J Alzheimers Dis, vol. 94, no. 3, pp. 993-1004, 2023.
G. Tumminelli, Di Donato, I., Guida, V., Rufa, A., De Luca, A., and Federico, A., “Oculodentodigital dysplasia with massive brain calcification and a new mutation of GJA1 gene.”, J Alzheimers Dis, vol. 49, no. 1, pp. 27-30, 2016.
G. Tumminelli, Di Donato, I., Guida, V., Rufa, A., De Luca, A., and Federico, A., “Oculodentodigital dysplasia with massive brain calcification and a new mutation of GJA1 gene.”, J Alzheimers Dis, vol. 49, no. 1, pp. 27-30, 2016.
D. A. Nation, Ho, J., and Yew, B., “Older Adults Taking AT1-Receptor Blockers Exhibit Reduced Cerebral Amyloid Retention.”, J Alzheimers Dis, vol. 50, no. 3, pp. 779-89, 2016.
D. A. Nation, Ho, J., and Yew, B., “Older Adults Taking AT1-Receptor Blockers Exhibit Reduced Cerebral Amyloid Retention.”, J Alzheimers Dis, vol. 50, no. 3, pp. 779-89, 2016.
A. Oulhaj, Jernerén, F., Refsum, H., A Smith, D., and de Jager, C. A., “Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 2, pp. 547-57, 2016.
C. R. Jack, Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., Roberts, R. O., Rocca, W. A., Boeve, B. F., and Petersen, R. C., “An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.”, Ann Neurol, vol. 71, no. 6, pp. 765-75, 2012.
P. Banerjee, Sahoo, A., Anand, S., Bir, A., and Chakrabarti, S., “The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 681-93, 2016.
G. Marwarha, Rostad, S., Lilek, J., Kleinjan, M., Schommer, J., and Ghribi, O., “Palmitate Increases β-site AβPP-Cleavage Enzyme 1 Activity and Amyloid-β Genesis by Evoking Endoplasmic Reticulum Stress and Subsequent C/EBP Homologous Protein Activation.”, J Alzheimers Dis, vol. 57, no. 3, pp. 907-925, 2017.
G. Marwarha, Rostad, S., Lilek, J., Kleinjan, M., Schommer, J., and Ghribi, O., “Palmitate Increases β-site AβPP-Cleavage Enzyme 1 Activity and Amyloid-β Genesis by Evoking Endoplasmic Reticulum Stress and Subsequent C/EBP Homologous Protein Activation.”, J Alzheimers Dis, vol. 57, no. 3, pp. 907-925, 2017.
G. Marwarha, Rostad, S., Lilek, J., Kleinjan, M., Schommer, J., and Ghribi, O., “Palmitate Increases β-site AβPP-Cleavage Enzyme 1 Activity and Amyloid-β Genesis by Evoking Endoplasmic Reticulum Stress and Subsequent C/EBP Homologous Protein Activation.”, J Alzheimers Dis, vol. 57, no. 3, pp. 907-925, 2017.
S. Beggiato, Borelli, A. Celeste, Ferraro, L., Tanganelli, S., Antonelli, T., and Tomasini, M. Cristina, “Palmitoylethanolamide Blunts Amyloid-β42-Induced Astrocyte Activation and Improves Neuronal Survival in Primary Mouse Cortical Astrocyte-Neuron Co-Cultures.”, J Alzheimers Dis, vol. 61, no. 1, pp. 389-399, 2018.
M. Jucker and Walker, L. C., “Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.”, Ann Neurol, vol. 70, no. 4, pp. 532-40, 2011.
N. Y. Kirson, J Andrews, S., Desai, U., King, S. B., Schonfeld, S., Birnbaum, H. G., Ball, D. E., and Kahle-Wrobleski, K., “Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 295-307, 2018.
L. - S. Liu, Bai, X. - Q., Gao, Y., Wu, Q., Ren, Z., Li, Q., Pan, L. - H., He, N. - Y., Peng, J., and Tang, Z. - H., “PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway.”, J Alzheimers Dis, vol. 57, no. 3, pp. 723-734, 2017.
P. Suppa, Hampel, H., Kepp, T., Lange, C., Spies, L., Fiebach, J. B., Dubois, B., and Buchert, R., “Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 51, no. 3, pp. 867-73, 2016.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.

Pages